Evidence map›Paper›PMID 39493926›Full record

ArticleTherapeutic advances in drug safety2024

Comparison of a single intravenous infusion of alfentanil or sufentanil combined with target-controlled infusion of propofol for daytime hysteroscopy: a randomized clinical trial.

Xiaofeng Lei, Tinghuan Zhang, Xuezhu Huang

Registry-linked trialAbstract read
In one paragraph

Article in Therapeutic advances in drug safety, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07713134 (Efficacy and Safety of the Biased μ-Opioid Receptor Agonist Oliceridine in Hysteroscopic Procedures), which is not on this map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07713134 nacompletednot on this mapstarted 2025, after this paper: background citation

Efficacy and Safety of the Biased μ-Opioid Receptor Agonist Oliceridine in Hysteroscopic Procedures

TypeinterventionalSponsorTangshan Maternal and Child Health HospitalRan2025 to 2026Enrolled225ConditionsHysteroscopy, AnalgeisaArmsSufentanil, Oliceridine
3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Trial
  2. Trial
  3. Trial
  4. Trial
  5. The median Effective Dose (EDBMC anesthesiology · 2025
    Trial
  6. Trial
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Xiaofeng LeiDepartment of Anesthesiology, Women and Children's Hospital of Chongqing Medical University (Chongqing Health Center for Women and Children), Chongqing, China.
Tinghuan ZhangDepartment of Anesthesiology, Chongqing Rongchang Health Center for Women and Children, Chongqing, China.
Xuezhu HuangDepartment of Anesthesiology, Women and Children's Hospital of Chongqing Medical University (Chongqing Health Center for Women and Children), 120 Longshan Road, Yubei District, Chongqing 401147, China.ORCID https://orcid.org/0000-0002-8019-9747

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: The administration of either alfentanil or sufentanil as a single injection, combined with target-controlled infusion (TCI) of propofol, represents a frequently employed anesthetic regimen for daytime hysteroscopy. Objectives: This study was designed to evaluate and compare the safety and efficacy of alfentanil and sufentanil in the context of daytime hysteroscopy. Design: A total of 160 patients, scheduled for daytime hysteroscopy, were randomly allocated into two groups: Group A and Group S respectively received alfentanil 10 μg/kg or sufentanil 0.15 μg/kg as a single intravenous injection. Both groups were given propofol with TCI for sedation. Methods: Monitoring of vital signs was conducted from pre-anesthesia through to 2 h postoperatively. The primary outcome measured was hypoxemia, defined as SpO Results: The analyses revealed that Group A had a significantly lower incidence of hypoxemia ( Conclusion: For daytime hysteroscopy, alfentanil at a dose of 10 μg/kg is safer than sufentanil at a dose of 0.15 μg/kg when combined with propofol TCI. Trial registration: This study was registered with the Chinese Clinical Trial Registry (The URL of registration is https://www.chictr.org.cn/showproj.html?proj=177784; registration number: ChiCTR2200063939). The date of first registration was September 21, 2022.

Indexed as

alfentanilambulatory surgical procedureshypoxiahysteroscopysufentanil

Identifiers

PMID39493926
PMCPMC11528634

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.